medroxyprogesterone acetate has been researched along with Embolism, Pulmonary in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (23.08) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Brynhildsen, J; Fredrikson, M; Hammar, M; Hoffmann, M; Spetz Holm, AC; Sundell, M | 1 |
| Anderson, GL; Aragaki, AK; Chlebowski, RT; Gass, M; Johnson, KC; Kuller, LH; Manson, JE; Prentice, RL; Rossouw, JE; Shadyab, AH; Stefanick, ML; Wactawski-Wende, J; Wallace, R | 1 |
| Anderson, G; Aragaki, AK; Beresford, SA; Cauley, JA; Chlebowski, RT; Eaton, CB; Gass, M; Howard, BV; Hsia, J; Jackson, RD; Johnson, KC; Kooperberg, C; Kuller, LH; LaCroix, AZ; Lewis, CE; Limacher, M; Liu, S; Manson, JE; Margolis, KL; Martin, LW; O'Sullivan, MJ; Ockene, JK; Powell, LH; Prentice, RL; Rossouw, JE; Simon, MS; Stefanick, ML; Thomson, CA; Van Horn, L; Vitolins, MZ; Wactawski-Wende, J; Wallace, RB; Wassertheil-Smoller, S | 1 |
| Aedo, S; Barriga, P; Blümel, JE; Brantes, S; Campodónico, Í; Cavada, G; Chedraui, P; Fica, J; Irribarra, C; Vallejo, M | 1 |
| Allison, M; Anderson, GL; Brzyski, R; Jackson, RD; Johnson, KC; Kuller, LH; Lane, DS; Langer, RD; Manson, JE; Ockene, J; Pettinger, M; Prentice, RL; Rossouw, JE; Sarto, G; Wactawski-Wende, J | 1 |
| Anderson, GL; Beresford, SA; Howard, BV; Jackson, RD; Johnson, KC; Kooperberg, C; Kotchen, JM; LaCroix, AZ; Ockene, J; Prentice, RL; Rossouw, JE; Stefanick, ML | 1 |
| Enserink, M | 1 |
| Heinemann, V; Parhofer, K | 1 |
| Shapiro, S | 1 |
| Kosaka, A; Sakaguchi, T; Watahiki, Y | 1 |
| Cass, I; Odunsi, K; Olive, DL; Sarrel, P; Zreik, TG | 1 |
| Barrett-Connor, E; Cauley, J; Furberg, C; Grady, D; Haskell, W; Hulley, S; Hunninghake, D; Knopp, R; Lowery, M; Satterfield, S; Schrott, H; Vittinghoff, E | 1 |
| Horikawa, K; Okada, Y | 1 |
6 trial(s) available for medroxyprogesterone acetate and Embolism, Pulmonary
| Article | Year |
|---|---|
Randomized Trial Evaluation of the Benefits and Risks of Menopausal Hormone Therapy Among Women 50-59 Years of Age.
Topics: Coronary Disease; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Hip Fractures; Humans; Medroxyprogesterone Acetate; Middle Aged; Neoplasms; Postmenopause; Proportional Hazards Models; Pulmonary Embolism; Stroke | 2021 |
Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.
Topics: Aged; Breast Neoplasms; Colorectal Neoplasms; Coronary Disease; Drug Therapy, Combination; Endometrial Neoplasms; Estrogens; Estrogens, Conjugated (USP); Female; Follow-Up Studies; Hip Fractures; Hormone Replacement Therapy; Humans; Medroxyprogesterone Acetate; Middle Aged; Postmenopause; Pulmonary Embolism; Quality of Life; Risk; Stroke; Treatment Outcome; United States | 2013 |
Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause.
Topics: Aged; Breast Neoplasms; Colorectal Neoplasms; Contraceptive Agents, Female; Coronary Disease; Endometrial Neoplasms; Estrogen Replacement Therapy; Estrogens; Estrogens, Conjugated (USP); Female; Follow-Up Studies; Fractures, Bone; Humans; Incidence; Medroxyprogesterone Acetate; Menopause; Middle Aged; Postmenopause; Progestins; Pulmonary Embolism; Retrospective Studies; Risk Factors; Stroke; Survival Rate; Thrombosis; Time Factors; Washington | 2009 |
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.
Topics: Aged; Breast Neoplasms; Clinical Trials Data Monitoring Committees; Colorectal Neoplasms; Coronary Disease; Endometrial Neoplasms; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Fractures, Bone; Humans; Medroxyprogesterone Acetate; Middle Aged; Myocardial Infarction; Postmenopause; Progesterone Congeners; Proportional Hazards Models; Pulmonary Embolism; Risk; Stroke; Survival Analysis; Thrombosis; Treatment Outcome | 2002 |
[Risk and benefits of hormone replacement therapy by postmenopausal women. WHI-Study].
Topics: Aged; Breast Neoplasms; Colorectal Neoplasms; Coronary Disease; Endometrial Neoplasms; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Fractures, Bone; Hormone Replacement Therapy; Humans; Incidence; Medroxyprogesterone Acetate; Middle Aged; Myocardial Infarction; Postmenopause; Progesterone Congeners; Proportional Hazards Models; Pulmonary Embolism; Risk Assessment; Stroke; Survival Analysis; Thrombosis; Treatment Outcome; United States; Women's Health | 2003 |
Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).
Topics: Aged; Biliary Tract Diseases; Biliary Tract Surgical Procedures; Cause of Death; Coronary Disease; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Follow-Up Studies; Fractures, Bone; Humans; Medroxyprogesterone Acetate; Neoplasms; Postmenopause; Pulmonary Embolism; Risk Factors; Survival Analysis; Thromboembolism; Treatment Outcome; Venous Thrombosis | 2002 |
7 other study(ies) available for medroxyprogesterone acetate and Embolism, Pulmonary
| Article | Year |
|---|---|
Pulmonary embolism in menopausal hormone therapy: a population-based register study.
Topics: Administration, Cutaneous; Case-Control Studies; Estrogen Replacement Therapy; Estrogens; Female; Humans; Medroxyprogesterone Acetate; Menopause; Progestins; Pulmonary Embolism; Risk Factors | 2022 |
Women's Health Initiative estrogen plus progestin clinical trial: a study that does not allow establishing relevant clinical risks.
Topics: Breast Neoplasms; Colorectal Neoplasms; Coronary Disease; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Hip Fractures; Humans; Medroxyprogesterone Acetate; Monte Carlo Method; Placebos; Proportional Hazards Models; Pulmonary Embolism; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Survival Rate; Women's Health | 2015 |
Women's health. The vanishing promises of hormone replacement.
Topics: Breast Neoplasms; Cardiovascular Diseases; Colorectal Neoplasms; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Fractures, Bone; Humans; Medroxyprogesterone Acetate; Menopause; Postmenopause; Pulmonary Embolism; Randomized Controlled Trials as Topic; Risk Factors; Selection Bias; Time Factors | 2002 |
Risks of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women's Health Initiative randomized controlled trial.
Topics: Bias; Breast Neoplasms; Contraceptive Agents, Female; Coronary Disease; Data Interpretation, Statistical; Estrogen Replacement Therapy; Estrogens; Estrogens, Conjugated (USP); Female; Humans; Incidence; Medroxyprogesterone Acetate; Pulmonary Embolism; Randomized Controlled Trials as Topic; Research Design; Risk; Stroke | 2003 |
[A case of breast cancer with thrombosis during treatment of lung metastasis].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Epirubicin; Female; Humans; Infusions, Intravenous; Lentinan; Lung Neoplasms; Medroxyprogesterone Acetate; Pulmonary Embolism; Radiography; Tamoxifen; Tegafur; Thrombophlebitis; Uracil | 1993 |
A case of fatal pulmonary thromboembolism associated with the use of intravenous estrogen therapy.
Topics: Drug Therapy, Combination; Estrogens, Conjugated (USP); Fatal Outcome; Female; Humans; Injections, Intravenous; Medroxyprogesterone Acetate; Middle Aged; Pulmonary Embolism | 1999 |
[A case of phlebothrombosis of lower extremity and pulmonary embolism due to progesterone].
Topics: Breast Neoplasms; Female; Humans; Medroxyprogesterone; Medroxyprogesterone Acetate; Middle Aged; Neoplasm Recurrence, Local; Pulmonary Embolism; Tamoxifen; Thrombophlebitis | 1992 |